AChE/BChE/BACE-1-IN-1 structure
|
Common Name | AChE/BChE/BACE-1-IN-1 | ||
---|---|---|---|---|
CAS Number | 1321361-13-0 | Molecular Weight | 350.38 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C19H21F3N2O | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of AChE/BChE/BACE-1-IN-1AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential[1]. |
Name | AChE/BChE/BACE-1-IN-1 |
---|
Description | AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential[1]. |
---|---|
Related Catalog | |
Target |
IC50: 0.058 μM (hAChE), 0.082 μM (hBChE), 0.115 μM (hBACE-1)[1] |
In Vivo | AChE/BChE/BACE-1-IN-1 (Compound 4k) (0-10 mg/kg; p.o.) ameliorates cognitive dysfunction against the scopolamine-induced amnesia model in the Y-maze test[1]. |
References |
Molecular Formula | C19H21F3N2O |
---|---|
Molecular Weight | 350.38 |